S&P 500   3,391.18 (+0.62%)
DOW   29,395.05 (+0.56%)
QQQ   237.17 (+1.04%)
AAPL   324.32 (+1.67%)
FB   217.59 (-0.10%)
MSFT   187.16 (-0.04%)
GOOGL   1,527.83 (+0.55%)
AMZN   2,184.37 (+1.33%)
CGC   21.68 (-1.23%)
NVDA   312.28 (+5.30%)
BABA   222.68 (+0.98%)
MU   59.72 (+3.41%)
GE   12.83 (+0.55%)
TSLA   923.66 (+7.60%)
AMD   59.15 (+3.97%)
T   38.61 (+0.89%)
ACB   1.71 (+4.27%)
F   8.01 (-0.62%)
NFLX   387.45 (-0.09%)
PRI   136.32 (+0.52%)
BAC   34.81 (+1.55%)
GILD   67.05 (+0.04%)
S&P 500   3,391.18 (+0.62%)
DOW   29,395.05 (+0.56%)
QQQ   237.17 (+1.04%)
AAPL   324.32 (+1.67%)
FB   217.59 (-0.10%)
MSFT   187.16 (-0.04%)
GOOGL   1,527.83 (+0.55%)
AMZN   2,184.37 (+1.33%)
CGC   21.68 (-1.23%)
NVDA   312.28 (+5.30%)
BABA   222.68 (+0.98%)
MU   59.72 (+3.41%)
GE   12.83 (+0.55%)
TSLA   923.66 (+7.60%)
AMD   59.15 (+3.97%)
T   38.61 (+0.89%)
ACB   1.71 (+4.27%)
F   8.01 (-0.62%)
NFLX   387.45 (-0.09%)
PRI   136.32 (+0.52%)
BAC   34.81 (+1.55%)
GILD   67.05 (+0.04%)
S&P 500   3,391.18 (+0.62%)
DOW   29,395.05 (+0.56%)
QQQ   237.17 (+1.04%)
AAPL   324.32 (+1.67%)
FB   217.59 (-0.10%)
MSFT   187.16 (-0.04%)
GOOGL   1,527.83 (+0.55%)
AMZN   2,184.37 (+1.33%)
CGC   21.68 (-1.23%)
NVDA   312.28 (+5.30%)
BABA   222.68 (+0.98%)
MU   59.72 (+3.41%)
GE   12.83 (+0.55%)
TSLA   923.66 (+7.60%)
AMD   59.15 (+3.97%)
T   38.61 (+0.89%)
ACB   1.71 (+4.27%)
F   8.01 (-0.62%)
NFLX   387.45 (-0.09%)
PRI   136.32 (+0.52%)
BAC   34.81 (+1.55%)
GILD   67.05 (+0.04%)
S&P 500   3,391.18 (+0.62%)
DOW   29,395.05 (+0.56%)
QQQ   237.17 (+1.04%)
AAPL   324.32 (+1.67%)
FB   217.59 (-0.10%)
MSFT   187.16 (-0.04%)
GOOGL   1,527.83 (+0.55%)
AMZN   2,184.37 (+1.33%)
CGC   21.68 (-1.23%)
NVDA   312.28 (+5.30%)
BABA   222.68 (+0.98%)
MU   59.72 (+3.41%)
GE   12.83 (+0.55%)
TSLA   923.66 (+7.60%)
AMD   59.15 (+3.97%)
T   38.61 (+0.89%)
ACB   1.71 (+4.27%)
F   8.01 (-0.62%)
NFLX   387.45 (-0.09%)
PRI   136.32 (+0.52%)
BAC   34.81 (+1.55%)
GILD   67.05 (+0.04%)
Log in

NASDAQ:LPTX - Leap Therapeutics Stock Price, Forecast & News

$2.88
+0.58 (+25.22 %)
(As of 02/19/2020 12:38 PM ET)
Today's Range
$2.35
Now: $2.88
$3.00
50-Day Range
$1.05
MA: $1.81
$2.30
52-Week Range
$0.57
Now: $2.88
$2.97
Volume106,513 shs
Average Volume645,117 shs
Market Capitalization$69.67 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LPTX
CUSIPN/A
Phone617-714-0360

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.62 per share

Profitability

Net Income$-23,140,000.00

Miscellaneous

Employees23
Market Cap$69.67 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive LPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.


Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics Inc (NASDAQ:LPTX) announced its earnings results on Thursday, November, 14th. The company reported ($0.33) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.33). View Leap Therapeutics' Earnings History.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Leap Therapeutics.

What price target have analysts set for LPTX?

3 analysts have issued twelve-month price objectives for Leap Therapeutics' shares. Their forecasts range from $2.50 to $6.00. On average, they expect Leap Therapeutics' stock price to reach $3.92 in the next year. This suggests a possible upside of 36.1% from the stock's current price. View Analyst Price Targets for Leap Therapeutics.

What is the consensus analysts' recommendation for Leap Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics.

Has Leap Therapeutics been receiving favorable news coverage?

Media stories about LPTX stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Leap Therapeutics earned a news impact score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Leap Therapeutics.

Are investors shorting Leap Therapeutics?

Leap Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totalling 1,160,000 shares, an increase of 23.1% from the January 15th total of 942,100 shares. Based on an average trading volume of 656,900 shares, the short-interest ratio is presently 1.8 days. Currently, 8.0% of the shares of the company are sold short. View Leap Therapeutics' Current Options Chain.

Who are some of Leap Therapeutics' key competitors?

What other stocks do shareholders of Leap Therapeutics own?

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the folowing people:
  • Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 65)
  • Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 50)
  • Mr. Augustine J. Lawlor, Chief Operating Officer (Age 63)

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include FMR LLC (2.73%). View Institutional Ownership Trends for Leap Therapeutics.

Which major investors are selling Leap Therapeutics stock?

LPTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. View Insider Buying and Selling for Leap Therapeutics.

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $2.88.

How big of a company is Leap Therapeutics?

Leap Therapeutics has a market capitalization of $69.60 million. The company earns $-23,140,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis. Leap Therapeutics employs 23 workers across the globe.View Additional Information About Leap Therapeutics.

What is Leap Therapeutics' official website?

The official website for Leap Therapeutics is http://www.leaptx.com/.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.


MarketBeat Community Rating for Leap Therapeutics (NASDAQ LPTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  230 (Vote Outperform)
Underperform Votes:  215 (Vote Underperform)
Total Votes:  445
MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel